The results were announced Monday in a conference in New Orleans.
AstraZeneca is emerging as a potential new contender in the booming obesity treatment market after its experimental ...
AstraZeneca’s updated fair value estimate has edged up from £163.06 to £165.09, a modest change that still matters if you ...
Deutsche Bank has kept its sell rating and 11,500p price target on AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results